Previous close | 128.38 |
Open | 131.40 |
Bid | 0.00 x 0 |
Ask | 0.00 x 0 |
Day's range | 123.92 - 131.40 |
52-week range | 74.70 - 140.32 |
Volume | |
Avg. volume | 43,456 |
Market cap | 550.833B |
Beta (5Y monthly) | 0.19 |
PE ratio (TTM) | 46.82 |
EPS (TTM) | 2.66 |
Earnings date | N/A |
Forward dividend & yield | 1.86 (1.45%) |
Ex-dividend date | 22 Mar 2024 |
1y target est | N/A |
Novo Nordisk stock: The weight-loss drug leader hit a buy point in the recent stock market rebound and is one of the best stocks to watch.
Drug and biotech companies are likely to see significant innovation. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), Novo Nordisk (NVO), Merck (MRK) and AbbVie (ABBV) are worth retaining in one's portfolio.
Bagsværd, Denmark, 24 April 2024 – At Novo Nordisk’s Annual General Meeting on 21 March 2024, it was decided to reduce the company’s B share capital from DKK 343,512,800 to DKK 339,012,800 by cancellation of part of the company’s portfolio of own B shares equal to a nominal value of DKK 4,500,000 divided into 45,000,000 B shares of DKK 0.10 each. Today, Novo Nordisk has registered the implementation of the reduction of the share capital with the Danish Business Authority and cancelled B shares a